These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18086564)

  • 1. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
    Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
    Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
    Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
    Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
    Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
    Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
    Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
    Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
    Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
    Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
    J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
    Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
    Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
    Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
    Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
    Jin Y; Chen Q; Lu Z; Chen B; Pan J
    Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
    Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
    Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
    Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
    Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
    Shen Y; Shi X; Pan J
    PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
    Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
    Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
    Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
    Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
    Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of MCP-1 and protein kinase C delta activation in human eosinophilic leukemia EoL-1 cells.
    Lee JS; Yang EJ; Kim IS
    Cytokine; 2009 Dec; 48(3):186-95. PubMed ID: 19664934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM; Liu JC
    J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.